ALK and lung carcinoma: A lung cancer with c-MET amplification also demonstrated high sensitivity to crizotinib, a tyrosine kinase inhibitor targeting the anaplastic lymphoma kinase gene (ALK), suggesting cancers with increased c-MET levels may be sensitive to ALK inhibitors [8].